

A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SABR) in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)

“Stablemates Trial”

First patient enrolled in study


The Stablemates trial has accrued its first patient at UT Southwestern Medical Center in Dallas.

The patient, a 57-year-old Spanish-speaking female, was a patient of Parkland Memorial Hospital, a public hospital owned by Dallas county. She was randomized to the surgical arm of the trial, and subsequently underwent sublobar resection at Parkland. Scott Reznik, M.D., UT Southwestern associate professor of cardiothoracic surgery, performed the surgery.

The enrolling physician was radiation oncologist Puneeth Iyengar, M.D., Ph.D., the local PI for UT Southwestern.



Puneeth Iyengar, M.D., Ph.D.



Scott Reznik, M.D.

Web site in development

The Stablemates trial will soon have a dedicated web site. Investigators will be able to view the latest version of the protocol, link to REDcap to enroll patients, read news related to the trial, and eventually share an educational video with patients.

QA for radiation

Feribus eaqui aut et, suntemporero mintis et haribus res evenia int.

Me omnime eos animin prae rectiae num quatio. Soloreium voloristio. Nequas alition sectibust asperum ariamet laccat aborendaepe dolut as mil moluptur? Velit labo. Ed mo consent vit qui oditius volupta voluptas ilicia sequi omnisim agniti rati ullicia dolori volo beria veliqui demped minihil igentia ditiones dolori omni renihit expliq-uid quam, si ab inus dolore sendenis simus incia sum quo eatatium exceatem eos doluptaspriet pratur rerrovid quiae quibeatum, quo magnis alitatis quibus deliatiis aut aut atem haribus citiis etur re dendeliqui dictatur?

Itatat magnatur ad unt, solor re nonsequis aut renda non porehent et quidipi scipienis incit do-lupta sum erestrume veliquam fugit, sit que

Ceptatectaque non et que nonsequi quam quam, ut et harum quasim et delistrum sapiciatiae deles plibusam remque nemporita sandam, sumquunt ex ent ut pratio cullibus nihicilles eiunt.

Study Co-Chair & Surgery QA	Hiran Fernando, MD hiran.fernando@bmc.org 617-638-5600
Study Co-Chair & Radiation QA.....	Robert Timmerman, MD robert.timmerman@utsw.edu 214.645.7651
Statistician	Chul Ahn, PhD chul.ahn@utsw.edu 214-648-9418
Regulatory	Rossana Berrios rossana.berrios@utsw.edu 214.648.1890
Research Manager	Jean Wu, RN, MSN, OCN jean.wu@utsw.edu 214.648.1892
Budget & Contracts	Margie Harper margarette.harper@utsw.edu 214.648.8038
Project Manager	Shinny Abraham shinny.abraham@utsw.edu 214.645.7695
Newsletter	Dee Hill dee.hill@utsw.edu 214.645.7650

Committed partners*

* Credentialed sites that have submitted the participation questionnaire

Allegheny General Hospital <i>Pittsburgh, PA</i>
Anne Arundel Medical Center <i>Annapolis, MD</i>
Boston Medical Center <i>Boston, MA</i>
CHUM - Notre Dame Hospital <i>Montreal, Canada</i>
City of Hope <i>Duarte, CA</i>
Curtis & Elizabeth Anderson Cancer Institute at Memorial University Medical Center <i>Savannah, GA</i>
Henry Ford Health System <i>Detroit, MI</i>
Intermountain - McKay Dee Hospital <i>Ogden, UT</i>
Intermountain Medical Center <i>Murray, UT</i>
London Health Sciences Centre <i>London, Ontario, Canada</i>
Mayo Clinic Arizona <i>Scottsdale, AZ</i>
Mayo Clinic Rochester <i>Rochester, MN</i>
Memorial Health System <i>Hollywood, FL</i>
Ochsner Medical Center <i>Jefferson, LA</i>
The Ohio State University Wexner Medical Center <i>Columbus, OH</i>
The Ottawa Hospital <i>Ottawa, Ontario, Canada</i>
Providence Health & Services <i>Portland, OR</i>
Rhode Island Hospital <i>Providence RI</i>
Swedish Cancer Institute <i>Seattle, WA</i>
University of California San Francisco Medical Center <i>San Francisco, CA</i>
University of Chicago Medicine <i>Chicago, IL</i>

University of Kentucky Health Care <i>Lexington, KY</i>
University of Louisville Physicians <i>Louisville, KY</i>
University of Maryland Medical Center <i>Baltimore, MD</i>
University of Tennessee Health Science Center <i>Memphis, TN</i>
University of Texas Southwestern Medical Center <i>Dallas, TX</i>
University of Virginia Health System <i>Charlottesville, VA</i>

Key eligibility

- ★ Biopsy confirmed non-small cell lung cancer
- ★ Tumor ≤ 4 cm maximum diameter
- ★ Tumor located peripherally within the lung (not touching any surface within 2 cm of the proximal bronchial tree in all directions). Patients with non-peripheral (central) tumors are NOT eligible.
- ★ No evidence of distant metastases
- ★ High risk for lobectomy (e.g. FEV1 $\leq 50\%$) but likely able to tolerate sublobar resection.

